Numerous evidence indicates that up-regulation of CD51 is significantly associated with cancer progression and poor prognosis in multiple types of cancers, such as gastric cancer (Wang et al., 2019), osteosarcoma (Pei et al., 2019), colorectal cancer (Flum et al., 2018), and nasopharyngeal carcinoma (Ding et al., 2017). This evidence concerns the gene ITGAV and cancer.